Clinical trial
Allogeneic Versus Autologous Hematopoietic Stem Cell Transplantation for Adult T Lymphoblastic Lymphoma as First-line Consolidation.
NCT06741813 is registered in ClinicalTrials.gov with Peking University People's Hospital as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Allogeneic Versus Autologous Hematopoietic Stem Cell Transplantation for Adult T Lymphoblastic Lymphoma as First-line Consolidation.
- Lead sponsor
- Peking University People's Hospital
- Phase
- Not applicable
- Overall status
- Not yet recruiting
- Start date
- January 1, 2025
- Completion date
- December 31, 2029
- Enrollment
- 230 (estimated)
- Sites
- Not reported
Conditions
As the registry lists them; a condition with its own page is linked.
t lymphoblastic lymphoma